@igcpharma.bsky.social IGC’s Phase 2 #CALMA trial for Alzheimer’s agitation adds a second site at SCB Research in Puerto Rico, advancing Hispanic inclusion in #clinicalresearch and addressing a critical need.

Full info: shorturl.at/HE7I9

#IGCPharma #Alzheimers #ClinicalTrials

IGC Pharma's Phase 2 clinical trial interim data demonstrates significant reduction in sleep disturbances

@igcpharma.bsky.social Interim results from IGC Pharma’s CALMA trial show IGC-AD1 reduces sleep issues in Alzheimer’s: ~71% at week 2, ~78% at week 6 vs. placebo. A promising alternative to Trazodone & Suvorexant.

Read the full press release: shorturl.at/jodv9

#CALMA #Alzheimers #Sleep #IGCPharma

On #WorldHealthDay, we honor the patients, caregivers, and healthcare heroes who inspire us. At IGC Pharma, we advance research to improve lives and protect long-term quality of life.

#IGCPharma #HealthForAll #HopeInHealing #ScienceWithPurpose

@igcpharma.bsky.social expands #IGC_AD1 Phase 2 #clinicaltrials to Hamilton Health Sciences in Canada, strengthening Alzheimer’s agitation research and accelerating patient enrollment.
clinicaltrials.gov/study/NCT055...

#IGCPharma #Alzheimers #Neurodegeneration #AlzheimersResearch

IGC Pharma Wins 2 Awards

@igcpharma.bsky.social Wins Two Awards for Alzheimer’s Research!

IGC Pharma has received Third Prize and the Disproportionate Impact Prize in the NIA's PREPARE Challenge! Our #AI-driven research.
drivendata.co/blog/prepare...

#AlzheimersResearch #AI #HealthcareInnovation #IGCPharma

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment - IGC Pharma, INC. IGC-AD1 demonstrates the potential to modify tau and improve spatial memory

@igcpharma.bsky.social announces #newdata supporting IGC-AD1 as a promising #treatment for #Alzheimer's. The #preclinical #research highlights IGC-AD1's positive effects on tau tangles and improvements in spatial #memory.

Learn more at: investor.igcpharma.com/igc-pharma-a...

#IGCPharma

Equity Analyst Coverage by A.G.P./Alliance Global Partners with a #Buy Recommendation and $3.50 #Price Target. A copy of the #analyst #report can be obtained directly from A.G.P./Alliance Global Partners: rb.gy/dtywbl

#IGCPharma #AlzheimersDisease #ClinicalTrials